Inflammation hypothesis of depression by IL-17

Despite high prevalence of depressive disorders, their etiopathogenesis has not been fully understood. Only around 2/3 of patients suffering from depression respond to the standard antidepressant treatment. Hence, further studies searching for possible pathological mechanisms and potential contribut...

Full description

Bibliographic Details
Main Author: Katarzyna Bliźniewska-Kowalska
Format: Article
Language:English
Published: Elsevier 2023-04-01
Series:Journal of Affective Disorders Reports
Online Access:http://www.sciencedirect.com/science/article/pii/S2666915323000628
_version_ 1797854452913274880
author Katarzyna Bliźniewska-Kowalska
author_facet Katarzyna Bliźniewska-Kowalska
author_sort Katarzyna Bliźniewska-Kowalska
collection DOAJ
description Despite high prevalence of depressive disorders, their etiopathogenesis has not been fully understood. Only around 2/3 of patients suffering from depression respond to the standard antidepressant treatment. Hence, further studies searching for possible pathological mechanisms and potential contributory factors to treatment-resistance are necessary in order to find new, effective and safe antidepressant therapies. Depression frequently coexists with other autoimmune disorders. Some studies reveal hat biological agents targeting interleukin 17 (IL-17), when used in patients with autoimmune diseases may have clinical efficacy in the treatment of depressive disorders. This presentation will address the inflammation hypothesis of depression, focusing on interleukin 17 (IL-17), among other proinflammatory cytokines, that might play an important role in the development of depressive disorders.
first_indexed 2024-04-09T20:07:23Z
format Article
id doaj.art-35b22f1919bd4c2ca089268bb0b78b4e
institution Directory Open Access Journal
issn 2666-9153
language English
last_indexed 2024-04-09T20:07:23Z
publishDate 2023-04-01
publisher Elsevier
record_format Article
series Journal of Affective Disorders Reports
spelling doaj.art-35b22f1919bd4c2ca089268bb0b78b4e2023-04-01T08:51:33ZengElsevierJournal of Affective Disorders Reports2666-91532023-04-0112100523Inflammation hypothesis of depression by IL-17Katarzyna Bliźniewska-Kowalska0Department of Adult Psychiatry, Medical University of Lodz, Aleksandrowska 159, Łódź, PolandDespite high prevalence of depressive disorders, their etiopathogenesis has not been fully understood. Only around 2/3 of patients suffering from depression respond to the standard antidepressant treatment. Hence, further studies searching for possible pathological mechanisms and potential contributory factors to treatment-resistance are necessary in order to find new, effective and safe antidepressant therapies. Depression frequently coexists with other autoimmune disorders. Some studies reveal hat biological agents targeting interleukin 17 (IL-17), when used in patients with autoimmune diseases may have clinical efficacy in the treatment of depressive disorders. This presentation will address the inflammation hypothesis of depression, focusing on interleukin 17 (IL-17), among other proinflammatory cytokines, that might play an important role in the development of depressive disorders.http://www.sciencedirect.com/science/article/pii/S2666915323000628
spellingShingle Katarzyna Bliźniewska-Kowalska
Inflammation hypothesis of depression by IL-17
Journal of Affective Disorders Reports
title Inflammation hypothesis of depression by IL-17
title_full Inflammation hypothesis of depression by IL-17
title_fullStr Inflammation hypothesis of depression by IL-17
title_full_unstemmed Inflammation hypothesis of depression by IL-17
title_short Inflammation hypothesis of depression by IL-17
title_sort inflammation hypothesis of depression by il 17
url http://www.sciencedirect.com/science/article/pii/S2666915323000628
work_keys_str_mv AT katarzynablizniewskakowalska inflammationhypothesisofdepressionbyil17